Brevilaterin B from Brevibacillus laterosporus has selective antitumor activity and induces apoptosis in epidermal cancer

• Published in: World journal of microbiology & biotechnology 2022-11, Vol.38 (11), p.201-201, Article 201
• Main Authors: Chen, Zhou, Wang, Lulu, Liu, Yangliu, Han, Panpan, Hong, Dan, Li, Siting, Ma, Aijin, Jia, Yingmin
• Format: Article
• Language: English
• Subjects: Annexin V; Anticancer properties; Antimicrobial agents; Antimicrobial peptides; Antitumor activity; Apoptosis; Applied Microbiology; Biochemistry; Biological activity; Biomedical and Life Sciences; Biotechnology; Brevibacillus laterosporus; Cancer; Cholecystokinin; Environmental Engineering/Biotechnology; Fluorescent indicators; Fungicides; Life Sciences; Membrane permeability; Membrane potential; Membranes; Microbiology; Mitochondria; Original Paper; Peptides; Physical characteristics
• ISSN: 0959-3993; 1573-0972
• DOI: 10.1007/s11274-022-03372-8

Brevilaterins as antimicrobial peptides (AMPs) secreted by a newly discovered species Brevibacillus laterosporus , had been demonstrated to display excellent antibacterial and antifungal activities; however, very limited information about their new bioactivity was ever developed. Herein, we discovered Brevilaterin B, an AMP produced by Br. laterosporus S62-9, exhibited a new anticancer activity and investigated its anticancer details. Proliferation, membrane permeability and apoptotic rate of cell lines were studied by methods of CCK-8 Assay, LDH Assay and Annexin V-FITC/PI Kits, respectively. ROS levels and mitochondrial membrane potential of tested cells were further detected through the fluorescent probes DCFH-DA and JC-1. Brevilaterin B exhibited broad-spectrum anticancer activity in a dose-dependent manner. It selectively inhibited the proliferation of epidermal cancer cell A431 but had no effect on its control normal cells in a dose of 2.0 µg/mL. In comparision, typical morphological characteristics of apoptosis and an apoptotic ratio of 71.0% in A431 were observed after treatment by 2.0–3.0 µg/mL of Brevilaterin B. The ROS levels increased by 21.3% and mitochondrial membrane potential reduced by 48.8% from A431 were further occurred, indicating Brevilaterin B’s anticancer action was mainly focus on the mitochondrion of cancer cells. In total, Brevilaterin B we reported above maybe believed to be a potential application as an anticancer medicament, increasing its commercial value.